证券日报网讯11月13日晚间，普洛药业（000739）发布公告称，截至2025年11月12日，本次回购方案已 实施完毕。公司实际回购时间区间为2025年4月30日至2025年11月12日，公司通过股票回购专用证券账 户以集中竞价交易方式累计回购公司股份10，442，300股，占公司目前总股本的0.90%。 ...

每经AI快讯，普洛药业（SZ 000739，收盘价：15.58元）11月13日晚间发布公告称，截至2025年11月12 日，本次回购方案已实施完毕。公司实际回购时间区间为2025年4月30日至2025年11月12日，公司通过 股票回购专用证券账户以集中竞价交易方式累计回购公司股份约1044万股，占公司目前总股本的 0.9%，最高成交价15.59元/股，最低成交价13.62元/股，成交总金额为人民币约1.5亿元回购资金总额为 人民币约1.5亿元。 2025年1至6月份，普洛药业的营业收入构成为：医药行业占比99.6%，其他业务占比0.4%。 截至发稿，普洛药业市值为180亿元。 每经头条（nbdtoutiao）——"银行直供房，不计成本卖！"有的半价出售，众多刚需还不知道！银行用 过的房很抢手，有人加价100万元抢拍 （记者 曾健辉） ...

格隆汇11月13日丨普洛药业(000739.SZ)公布,截至2025年11月12日，本次回购方案已实施完毕。公司实 际回购时间区间为2025年4月30日至2025年11月12日，公司通过股票回购专用证券账户以集中竞价交易 方式累计回购公司股份1044.23万股，占公司目前总股本的0.90%，最高成交价15.59元/股，最低成交价 13.62元/股，成交总金额为人民币1.50亿元（不含交易费用）, 回购资金总额为人民币1.50亿元（含交易 费用）。 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-64 普洛药业股份有限公司 关于股份回购完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2025年2月19日召开第九届 董事会第十次会议审议通过了《关于回购公司股份方案的议案》，同意公司使用 自有资金以集中竞价交易方式回购公司部分股份，用于实施公司股权激励或员工 持股计划。本次回购股份价格不超过人民币22元/股（含），回购资金总额不低 于人民币7,500万元（含）且不超过人民币15,000万元（含）。具体回购股份数 量以回购期限届满或回购股份实施完毕时实际回购股份数量为准。回购期限为自 公司董事会审议通过回购股份方案之日起12个月内。具体内容详见公司分别于 2025 年 2 月 20 日 、 2025 年 2 月 21 日 在 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露的《第九届董事会第十次会议决议公告》 （公告编号：2025-04）、《关于回购公司股份方案的公告》（公告 ...

Core Viewpoint - The company announced a share buyback plan, indicating a strategic move to enhance shareholder value and potentially support stock price stability [1] Summary by Relevant Sections Share Buyback Details - The company will repurchase a total of 10,442,300 shares from April 30 to November 12, 2025, which represents 0.90% of the current total share capital [1] - The maximum transaction price for the buyback is set at 15.59 yuan per share, while the minimum price is 13.62 yuan per share [1] - The total amount for the buyback is 150 million yuan, including transaction fees, funded by the company's own resources and loans from financial institutions [1] Compliance and Impact - The buyback plan complies with relevant regulations and does not have a significant impact on the company's overall operations or its listing status [1] - The repurchased shares are intended for employee stock ownership plans or equity incentives, with any unused shares within 36 months to be canceled [1]

Macroeconomic Insights - Global asset performance shows mixed results, with the Hang Seng Index up 1.29% and the Shanghai Composite Index up 1.08%, while developed markets like the S&P 500 fell by 1.63%[6] - In October, the U.S. ISM Manufacturing PMI declined, indicating economic slowdown, while consumer confidence continued to drop according to the University of Michigan index[7] Inflation and Prices - October CPI in China rose by 0.2% year-on-year, while PPI decreased by 2.1%, indicating a stable inflation environment with core service prices reaching their highest level since March 2024[11] - The rise in core CPI is attributed to reduced food drag and increased service contributions, with gold prices significantly impacting jewelry costs[13] Trade and Exports - In October, China's exports fell by 1.1% year-on-year, while imports grew by 1.0%, leading to a slight decrease in trade surplus[16] - The export structure shows weakness in non-U.S. markets, particularly the EU, while exports to the U.S. and ASEAN remained strong[18] Investment Strategies - The asset allocation report suggests an overweight position in Chinese A-shares and industrial commodities, with equity allocation set at 45% and bonds at 45%[22] - The report emphasizes the importance of AI industry trends and the potential for volatility in global equity markets, recommending a focus on quality assets[23] Market Dynamics - The trading activity has decreased, with turnover rates and transaction volumes declining across indices, indicating a cautious market sentiment[28] - The report highlights a decrease in northbound capital flow, with a net outflow of 2.6 billion CNY in the recent week, reflecting investor sentiment shifts[34]

Core Viewpoint - Prolo Pharmaceutical's wholly-owned subsidiary, Zhejiang Prolo Jiayuan Pharmaceutical Co., Ltd., has received the Certificate of Suitability (CEP) for Venlafaxine Hydrochloride from the European Medicines Agency [2] Group 1 - The CEP certificate indicates that the product meets the European Pharmacopoeia standards, which is crucial for market access in Europe [2] - This certification may enhance the company's competitive position in the European pharmaceutical market [2] - The approval reflects the company's commitment to quality and regulatory compliance in its product offerings [2]

Core Viewpoint - Prolo Pharmaceutical's subsidiary, Zhejiang Prolo Jiayuan Pharmaceutical Co., Ltd., has received the CEP certificate for Venlafaxine Hydrochloride from the European Directorate for the Quality of Medicines (EDQM), indicating the product's compliance with European quality standards and enhancing the company's potential for international market expansion [1] Group 1 - Prolo Pharmaceutical's subsidiary has been recognized with a CEP certificate for Venlafaxine Hydrochloride, a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat various types of depression and generalized anxiety disorder [1] - The receipt of the CEP certificate signifies the recognition and affirmation of the quality of the raw material by the European regulatory market [1] - This certification allows the product to enter the EU market and other markets that recognize the CEP certificate, positively impacting the company's international market expansion efforts [1]

Core Viewpoint - The announcement highlights that Zhejiang Prolo Home Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Prolo Pharmaceutical, has received the Certificate of Suitability (CEP) for Venlafaxine Hydrochloride from the European Medicines Agency, indicating the quality recognition of this active pharmaceutical ingredient in the European market [1] Group 1 - The CEP certificate for Venlafaxine Hydrochloride signifies the product's compliance with European pharmacopoeia standards [1] - Venlafaxine Hydrochloride is used for treating various types of depression, including anxiety-related depression and generalized anxiety disorder [1] - The certification allows the product to enter the EU market and other markets that recognize the CEP certificate, facilitating international market expansion for the company [1]

Core Viewpoint - Prolo Pharmaceutical (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Prolo Jiayuan Pharmaceutical Co., Ltd., received the Certificate of Suitability (CEP) for Venlafaxine Hydrochloride from the European Directorate for the Quality of Medicines (EDQM) [1] Group 1 - The CEP certificate is significant for Venlafaxine Hydrochloride, which is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) [1] - Venlafaxine Hydrochloride is used for treating various types of depression, including depression with anxiety, and generalized anxiety disorder [1]